Nitrazepam Ennogen Ip (Nitrazepam)

Nitrazepam binds to the benzodiazepine site on the GABA‑A receptor, increasing the receptor’s affinity for the inhibitory neurotransmitter GABA. This enhances chloride ion influx, hyperpolarising neurons and reducing neuronal excitability, which produces sedative, anxiolytic, muscle‑relaxant and anticonvulsant effects.

The appropriate dose of nitrazepam is determined by the prescribing clinician based on the patient’s age, clinical condition, response to therapy and any concomitant medications. Dosage regimens are individualized and should follow local prescribing guidelines and the prescriber’s judgment.

Nitrazepam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding; because the drug passes into milk, caution is advised and alternatives should be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nitrazepam Ennogen Ip. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nitrazepam is a long‑acting benzodiazepine with a relatively slow onset compared with agents such as lorazepam or alprazolam. Its potency is moderate, and it has a half‑life that supports once‑daily dosing for insomnia or anxiety. Choice of benzodiazepine depends on the clinical indication, desired duration of action and patient‑specific factors.

Nitrazepam should be stored at ambient temperature below 25 °C, in its original container, protected from moisture, light and excessive heat. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discoloured.

Nitrazepam is taken orally, usually with a glass of water. It may be taken with or without food; however, a consistent approach (with or without meals) helps maintain stable absorption. Tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include respiratory depression, especially when combined with other CNS depressants; severe skin reactions such as Stevens‑Johnson syndrome; emergence of suicidal thoughts or worsening depression; dependence and withdrawal seizures upon abrupt discontinuation; and profound sedation that can impair the ability to operate machinery or drive.

Nitrazepam is contraindicated in individuals with known hypersensitivity to nitrazepam or other benzodiazepines, patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, and those with severe hepatic impairment. Caution is also required in patients with a history of substance dependence or severe depression.